price
BB
NASDAQ · BBOT
BridgeBio Oncology Therapeutics Inc.
Healthcare · Biotechnology
$4.88
Down-$0.17 (-3.37%)
Updated Sep 16, 2026, 1:01 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -2.62
- Dividend yield
- 0.00%
- 52-week range
- $4.85 – $14.87
- Volume
- 629.2K
- Avg. volume
- 237.22K
Price performance
BBOT price history
1M range · 20 trading sessions · Daily adjusted prices
BBOT closed at $4.88 after 20 trading sessions, down 45.47% for the selected period.
- Last close
- $4.88
- Period change
- -45.47%
- Period low
- $4.88
- Period high
- $9.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.01 | $5.015 | $4.72 | $4.88 | 629.2K |
| Sep 14, 2026 | $4.91 | $5.18 | $4.85 | $5.05 | 956.1K |
| Sep 11, 2026 | $5.53 | $5.616 | $4.90 | $4.95 | 1.63M |
| Sep 10, 2026 | $6.785 | $6.785 | $5.48 | $5.52 | 2.79M |
| Sep 9, 2026 | $8.86 | $8.86 | $6.295 | $6.755 | 1.5M |
| Sep 8, 2026 | $8.88 | $9.05 | $8.775 | $8.86 | 154.11K |
| Sep 4, 2026 | $8.80 | $9.06 | $8.65 | $8.98 | 117.62K |
| Sep 3, 2026 | $8.93 | $9.0411 | $8.66 | $8.90 | 139.21K |
| Sep 2, 2026 | $8.81 | $9.185 | $8.73 | $8.89 | 238.88K |
| Sep 1, 2026 | $8.70 | $8.90 | $8.535 | $8.82 | 146.13K |
| Aug 31, 2026 | $8.72 | $9.195 | $8.4101 | $8.80 | 476.04K |
| Aug 28, 2026 | $9.16 | $9.16 | $8.69 | $8.74 | 195.04K |
| Aug 27, 2026 | $9.19 | $9.315 | $9.06 | $9.18 | 385.27K |
| Aug 26, 2026 | $9.36 | $9.47 | $9.04 | $9.26 | 247.15K |
| Aug 25, 2026 | $9.24 | $9.4725 | $9.18 | $9.37 | 197.97K |
| Aug 24, 2026 | $9.10 | $9.3575 | $8.80 | $9.14 | 338.52K |
| Aug 21, 2026 | $9.19 | $9.4351 | $9.03 | $9.08 | 171.57K |
| Aug 20, 2026 | $9.55 | $9.78 | $9.08 | $9.08 | 203.26K |
| Aug 19, 2026 | $9.16 | $9.72 | $9.14 | $9.60 | 414.32K |
| Aug 18, 2026 | $9.02 | $9.125 | $8.82 | $8.95 | 446.87K |
Latest BBOT news
The latest Smart Investors Daily articles mentioning BBOT.
Stock researchCompany · Forecast
Loading stock research…